Thyme Bio announces financial results and company progress for the first half of 2020.

Introduction: First half of the total revenue of 984 million yuan, Dabershu ® (Syndili single anti-injection) sales revenue of 921 million yuan.
27, 2020, Thyda Biopharmaceuticals announced its financial results and company progress for the first half of 2020.
total revenue for the six months ended June 30, 2020 was RMB984 million, including RMB921 million from the sales revenue of Dabershu ® (Syndili single anti-injection) for the six months ended June 30, 2020.
In June 2020, Dayo and ® (Beval pearl single anti-injection) were officially approved by the State Drug Administration (NMPA) for the treatment of patients with advanced non-small cell lung cancer and metastatic colorectal cancer in China, becoming the company's second product to enter the commercial phase.
NMPA has officially accepted Dabershu® a new adaptation application for first-line non-squamous non-small cell lung cancer and first-line squamous non-small cell lung cancer.
In an oral presentation at the WCLC online thematic forum, Dabershu® Phase III clinical trial data for first-line non-squamous non-small cell lung cancer was published online on the same day as the journal Journal of Thoracic Oncology, a leading international journal in the field of lung cancer.
four products enter the registered or critical clinical phase, including IBI-310 (anti-CTLA-4 monoclonal antibody), IBI-306 (anti-PCSK9 monoclonal antibody), IBI-375 (pemigatinib, FGFR inhibitor) and IBI-376 (PI3K inhibitor).
strategic partnership with Roche has enabled us to discover and develop 2:1 pairs of specific T-cell antibodies (TCB) and its universal CAR-T platform using several Roche technologies.
Signed a $1 billion strategic agreement with Lilly to grant Lilly exclusive rights to Dabershu ® outside China, and Xinha Bio will receive a double-digit net sales commission.
2020 is the year when our mission officially landed and the year we laid the foundation for Xinda Bio's leapfrog development," said Dr. Yu Dechao, founder, chairman and president of Essida Bio.
despite the challenges posed by the new crown outbreak, our businesses have achieved remarkable results.
As the only PD-1 inhibitor to enter the national health insurance catalog, Dabershu ® continued to increase sales momentum in the first half of this year, allowing more ordinary people to enjoy the health benefits of scientific and technological progress®
, we have made significant progress in product development, registration promotion, capacity improvement and other aspects of the company's development.
recently, we have also expanded our strategic partnership with Lilly to expand the areas of cooperation ® the Dabershu region to the world.
This is the first time that China's independent research and development, has been listed polymer drugs to the overseas market successfully authorized to the world's top 500 pharmaceutical companies, but also marks our innovative product pipeline into the global market this strategy has made substantial progress, Xinda biological mission to further land, for the benefit of more global patients.
expects to see the approval of two other biosynthic drugs in the second half of this year or early next year.
At the same time, we will submit Dabershu® applications for new adaptations to second-line lung and liver cancer, continue to advance more than 50 ongoing clinical studies, enrich our innovative product chain, and continue to bring more valuable drugs to patients using our comprehensive integrated platform throughout the drug lifecycle.
we believe these developments will also help Xinda Bio continue to create value for shareholders and employees and achieve long-term sustainability for the company.
"s recent business development highlights the company has successfully established a 23-product research and development pipeline covering a wide range of new and well-documented therapeutic targets and drug models (including monoclonal antibodies, dual-specific antibodies, fusion proteins, CAR-T and small molecules), covering a number of key therapeutic areas such as oncology, metabolism, immunology and ophthalmological diseases.
.